Savas Ozsu
Research Subjects
Savas Ozsu has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Tevfik Özlü
Department of Pulmonary Medicine, Faculty of Medicine, Karadeniz Technical University, Trabzon 61080, Turkey
3 shared publications - Asım Örem
Karadeniz Teknik Üniversitesi
2 shared publications - Hayriye Bektaş Aksoy
Department of Pulmonary Medicine, Giresun University, Faculty of Medicine, Giresun, Türkiye
2 shared publications - Yilmaz Bulbul
Faculty of Medicine, Department of Chest Diseases, Karadeniz Technical University, Trabzon, Turkey
2 shared publications - Funda Öztuna
Chest Diseases, Karadeniz Technical University, Medical Faculty, Trabzon, Turkey
1 shared publication - Mustafa Buğra Coşkuner
Department of Pulmonary Diseases Aksaray University School of Medicine Aksaray Turkey
1 shared publication
Latest Publications
- Open Access
- 30 April 2024
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 11 (5) , 150-156
Role of Osteopontin and NGAL in Differential Diagnosis of Acute Exacerbations of COPD and Pneumonia
Objective: Chronic Obstructive Pulmonary Diesase (COPD) is an inflammatory lung disease that progresses with attacks. Pneumonia is an infectious lung disease that progresses with lung infiltrations. Osteopontin (OP) is a cytokine which participates in inflammation. Neutrophil Gelatinase Associated Lipocalin (NGAL) is an antimicrobial peptide with neutrophil activation and antibacterial properties. In this study, serum OP and NGAL levels were assayed in COPD exacerbation, stabile COPD and pneumonia. The aim of our study is to assess the importance of NGAL and OP levels as biomarkers in the differential diagnosis of COPD and pneumonia. Material and Methods: One hundred twenty consecutive patients who were admitted to our department between May 2011 and August 2013 were included in the study. Serum OP and NGAL levels were measured with ELISA method within 24 hours following the determination of diagnosis. COPD acute exacerbation (AE-COPD) group was comprised of 95 patients (87 male and mean age 69.0±10.6), and the pneumonia group was comprised of 25 patients (16 male and mean age 57.5±22.9). Serum OP and NGAL levels of the patients in the AE-COPD group were re-measured within 30-45 days following acute exacerbation in stabile period. Results: Serum OP levels were higher in the pneumonia group compared to the AE-COPD group (93.47 ng/ml vs 53.10 ng/ml; p84 ng/ml is an independent predictor that increases risk for pneumonia more than 8-fold (95% CI, 2.43-26.59). Sensitivity and specificity of OP in the differentiation of pneumonias from AE-COPD were determined to 80% and 92%, respectively. Serum NGAL levels also increased as COPD severity increased and was found to be statistically significant (p: 0.032). Conclusion: It has been indicated that serum osteopontin level can be an independent predictor in differentiating COPD exacerbation from pneumonia. Additionally, as COPD severity (stage) increases, serum NGAL levels also increase, which may be helpful in assessing the severity of COPD.
- 30 April 2024
- Published by Lycia Press London UK in Medical Science and Discovery
- Vol. 11 (5) , 150-156
Open AccessRole of Osteopontin and NGAL in Differential Diagnosis of Acute Exacerbations of COPD and Pneumonia
Objective: Chronic Obstructive Pulmonary Diesase (COPD) is an inflammatory lung disease that progresses with attacks. Pneumonia is an infectious lung disease that progresses with lung infiltrations. Osteopontin (OP) is a cytokine which participates in inflammation. Neutrophil Gelatinase Associated Lipocalin (NGAL) is an antimicrobial peptide with neutrophil activation and antibacterial properties. In this study, serum OP and NGAL levels were assayed in COPD exacerbation, stabile COPD and pneumonia. The aim of our study is to assess the importance of NGAL and OP levels as biomarkers in the differential diagnosis of COPD and pneumonia. Material and Methods: One hundred twenty consecutive patients who were admitted to our department between May 2011 and August 2013 were included in the study. Serum OP and NGAL levels were measured with ELISA method within 24 hours following the determination of diagnosis. COPD acute exacerbation (AE-COPD) group was comprised of 95 patients (87 male and mean age 69.0±10.6), and the pneumonia group was comprised of 25 patients (16 male and mean age 57.5±22.9). Serum OP and NGAL levels of the patients in the AE-COPD group were re-measured within 30-45 days following acute exacerbation in stabile period. Results: Serum OP levels were higher in the pneumonia group compared to the AE-COPD group (93.47 ng/ml vs 53.10 ng/ml; p84 ng/ml is an independent predictor that increases risk for pneumonia more than 8-fold (95% CI, 2.43-26.59). Sensitivity and specificity of OP in the differentiation of pneumonias from AE-COPD were determined to 80% and 92%, respectively. Serum NGAL levels also increased as COPD severity increased and was found to be statistically significant (p: 0.032). Conclusion: It has been indicated that serum osteopontin level can be an independent predictor in differentiating COPD exacerbation from pneumonia. Additionally, as COPD severity (stage) increases, serum NGAL levels also increase, which may be helpful in assessing the severity of COPD.
- 1 January 2020
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 68 (3) , 293-304
The cost of pulmonary thromboembolism treatment
Introduction: Primary aim of this study is to determine the financial burden of Vitamin K Antagonists (VKA), low molecular weight heparins (LMWH) and new oral anticoagulants (NOAC) which are used in the treatment of the pulmonary thromboembolism (PTE). Secondary aim is to show long term complications of the treatment options. Materials and Methods: The patients who are diagnosed with PTE between May 2016 and March 2018 at Faculty of Medicine Karadeniz Technical University Hospital were observed prospectively. Hospitalization costs were calculated on patients who were treated only for PTE by hospitalized in the Chest Diseases Service in the acute period. Maintenance costs were calculated over all patients who regulary admitted to our outpatient clinic with the diagnosis of PIE. Data were presented as mean +/- SD and median +/- interquartilee range. A p-value of < 0.05 was accepted to be significant. Results: Fifty five (37.2%) of the patients were male, 93 (62.8%) were female and the median age was 68 (range 18-95). The median hospitalization time and cost of patients who are discharged with VKA (n: 22) compared with patients discharged with LMWH (n: 22) was found to be increased (1316.82 TL 7,5 days / 803.36 TL, 5 days p< 0.001). Statistical analysis could not be performed with NOAC (n: 2). In the analysis of sixth month costs, LMWH cost was found to be higher than VKA cost (6.927.15 +/- 2.687.67 I L/698.29 +/- 483.51 U. p< 0.001). However VKA treatment tended to be less expensive than treatment with NOACs (698.29 +/- 483.51 TL/1.050.81 +/- 300.28 TL p= 0.140). Conclusion: In the acute period of PTE, VKA increases the length of hospitalization and hospital costs in patients treated at the hospital. In the maintenance period, VKA tends to have a lower cost compared to NOACs.
- 1 January 2020
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 68 (3) , 293-304
The cost of pulmonary thromboembolism treatment
Introduction: Primary aim of this study is to determine the financial burden of Vitamin K Antagonists (VKA), low molecular weight heparins (LMWH) and new oral anticoagulants (NOAC) which are used in the treatment of the pulmonary thromboembolism (PTE). Secondary aim is to show long term complications of the treatment options. Materials and Methods: The patients who are diagnosed with PTE between May 2016 and March 2018 at Faculty of Medicine Karadeniz Technical University Hospital were observed prospectively. Hospitalization costs were calculated on patients who were treated only for PTE by hospitalized in the Chest Diseases Service in the acute period. Maintenance costs were calculated over all patients who regulary admitted to our outpatient clinic with the diagnosis of PIE. Data were presented as mean +/- SD and median +/- interquartilee range. A p-value of < 0.05 was accepted to be significant. Results: Fifty five (37.2%) of the patients were male, 93 (62.8%) were female and the median age was 68 (range 18-95). The median hospitalization time and cost of patients who are discharged with VKA (n: 22) compared with patients discharged with LMWH (n: 22) was found to be increased (1316.82 TL 7,5 days / 803.36 TL, 5 days p< 0.001). Statistical analysis could not be performed with NOAC (n: 2). In the analysis of sixth month costs, LMWH cost was found to be higher than VKA cost (6.927.15 +/- 2.687.67 I L/698.29 +/- 483.51 U. p< 0.001). However VKA treatment tended to be less expensive than treatment with NOACs (698.29 +/- 483.51 TL/1.050.81 +/- 300.28 TL p= 0.140). Conclusion: In the acute period of PTE, VKA increases the length of hospitalization and hospital costs in patients treated at the hospital. In the maintenance period, VKA tends to have a lower cost compared to NOACs.
- 4 April 2015
- Published by Springer Nature in Lung
- Vol. 193 (4) , 559-565
Value of Cardiac Troponin and sPESI in Treatment of Pulmonary Thromboembolism at Outpatient Setting
Currently, guidelines do not recommend any standard approach for treatment of pulmonary thromboembolism (PTE) at outpatient setting. We investigated the efficacy and safety of a 90-day anticoagulant treatment of outpatients diagnosed with PTE who had negative troponin levels and low-risk simplified pulmonary embolism severity index (sPESI) at presentation. This prospective cohort study included a total of 206 patients with objectively confirmed acute symptomatic PTE. Any troponin negative (cTn-) and low sPESI patients (as classified Group-1) were treated in outpatient setting. The primary endpoint was all-cause mortality during the first 90 days, and the secondary endpoint included non-fatal symptomatic recurrent PTE or non-fatal major bleeding. Presence of cancer was excluded from sPESI score. Fifty-two of 206 patients were eligible for had Group-1, and 31 were treated at outpatients settings. The 90-day all-cause mortality rate was 3.2 % among patients who received outpatient treatment. Otherwise cTn+ and high-risk sPESI 90-day mortality rate was 43.7 %. No difference was found in terms of secondary endpoints between the patients who received outpatient treatment and those who received inpatient treatment in Group-1 (p = NS). In our study, cancer was present in 16 (51.6 %) of the 31 outpatients. We observed that patients with acute PTE, low-risk sPESI, and negative troponin levels can be safely treated in the outpatient settings. Also the presence of cancer alone does not necessitate hospitalization.
- 4 April 2015
- Published by Springer Nature in Lung
- Vol. 193 (4) , 559-565
Value of Cardiac Troponin and sPESI in Treatment of Pulmonary Thromboembolism at Outpatient Setting
Currently, guidelines do not recommend any standard approach for treatment of pulmonary thromboembolism (PTE) at outpatient setting. We investigated the efficacy and safety of a 90-day anticoagulant treatment of outpatients diagnosed with PTE who had negative troponin levels and low-risk simplified pulmonary embolism severity index (sPESI) at presentation. This prospective cohort study included a total of 206 patients with objectively confirmed acute symptomatic PTE. Any troponin negative (cTn-) and low sPESI patients (as classified Group-1) were treated in outpatient setting. The primary endpoint was all-cause mortality during the first 90 days, and the secondary endpoint included non-fatal symptomatic recurrent PTE or non-fatal major bleeding. Presence of cancer was excluded from sPESI score. Fifty-two of 206 patients were eligible for had Group-1, and 31 were treated at outpatients settings. The 90-day all-cause mortality rate was 3.2 % among patients who received outpatient treatment. Otherwise cTn+ and high-risk sPESI 90-day mortality rate was 43.7 %. No difference was found in terms of secondary endpoints between the patients who received outpatient treatment and those who received inpatient treatment in Group-1 (p = NS). In our study, cancer was present in 16 (51.6 %) of the 31 outpatients. We observed that patients with acute PTE, low-risk sPESI, and negative troponin levels can be safely treated in the outpatient settings. Also the presence of cancer alone does not necessitate hospitalization.
- Open Access
- 15 January 2015
- Published by Galenos Yayinevi in Türk Toraks Dergisi
- Vol. 16 (1) , 33-35
A Rare Cause of Chylothorax: Hennekam Syndrome
Hennekam syndrome was defined as a syndrome characterized by a new autosomal recessive, severe lymphedema in legs, face and genitalia with intestinal lymphangiectasia, various face anomalies and severe mental retardation. A 21 years old male patient was examined due to bilateral pleural effusion. There were edema in both legs and eyelids, swelling in the scrotum and operation scar, broad forehead and face, depressed nasal bridge, epicanthal folds and micrognathia in the physical examination. Chylothorax was diagnosed due to level of pleural triglyceride (650 mg/dL). Lymphatic flow delayed in both lower extremities in lymphoscintigraphy. The patient was diagnosed as Hennekam syndrome due to face anomalies, lymphedema, epilepsy, chylothorax and mild mental retardation.
- 15 January 2015
- Published by Galenos Yayinevi in Türk Toraks Dergisi
- Vol. 16 (1) , 33-35
Open AccessA Rare Cause of Chylothorax: Hennekam Syndrome
Hennekam syndrome was defined as a syndrome characterized by a new autosomal recessive, severe lymphedema in legs, face and genitalia with intestinal lymphangiectasia, various face anomalies and severe mental retardation. A 21 years old male patient was examined due to bilateral pleural effusion. There were edema in both legs and eyelids, swelling in the scrotum and operation scar, broad forehead and face, depressed nasal bridge, epicanthal folds and micrognathia in the physical examination. Chylothorax was diagnosed due to level of pleural triglyceride (650 mg/dL). Lymphatic flow delayed in both lower extremities in lymphoscintigraphy. The patient was diagnosed as Hennekam syndrome due to face anomalies, lymphedema, epilepsy, chylothorax and mild mental retardation.